Morgan Stanley United Therapeutics Corp Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in United Therapeutics Corp stock. As of the latest transaction made, Morgan Stanley holds 401,463 shares of UTHR stock, worth $146 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

401,463

Previous 806,988 50.25%

Holding current value

$146 Million

Previous $257 Million 44.04%

% of portfolio

0.01%

Previous 0.02%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$311.04 - $363.55 $126 Million - $147 Million	-405,525 Reduced 50.25%	401,463 $144 Million
Q2 2024 Oct 17, 2024	BUY	$228.26 - $319.04 $61.8 Million - $86.4 Million	270,780 Added 50.5%	806,988 $257 Million
Q2 2024 Aug 14, 2024	BUY	$228.26 - $319.04 $61.8 Million - $86.4 Million	270,780 Added 50.5%	806,988 $257 Million
Q1 2024 Oct 17, 2024	SELL	$210.76 - $249.51 $57.1 Million - $67.6 Million	-270,780 Reduced 33.55%	536,208 $123 Million
Q1 2024 Aug 16, 2024	BUY	$210.76 - $249.51 $16.1 Million - $19.1 Million	76,476 Added 16.63%	536,208 $123 Million
Q1 2024 May 15, 2024	BUY	$210.76 - $249.51 $16.1 Million - $19.1 Million	76,476 Added 16.63%	536,208 $123 Million
Q4 2023 Aug 16, 2024	SELL	$214.88 - $256.94 $74.6 Million - $89.2 Million	-347,256 Reduced 43.03%	459,732 $101 Million
Q4 2023 Feb 13, 2024	BUY	$214.88 - $256.94 $22.6 Million - $27.1 Million	105,331 Added 29.72%	459,732 $101 Million
Q3 2023 Nov 15, 2023	BUY	$211.82 - $248.24 $9.66 Million - $11.3 Million	45,625 Added 14.78%	354,401 $80 Million
Q2 2023 Aug 14, 2023	SELL	$205.19 - $232.99 $7 Million - $7.95 Million	-34,116 Reduced 9.95%	308,776 $68.2 Million
Q1 2023 May 15, 2023	SELL	$212.99 - $276.17 $9.78 Million - $12.7 Million	-45,913 Reduced 11.81%	342,892 $76.8 Million
Q4 2022 Feb 14, 2023	BUY	$205.95 - $280.43 $27.3 Million - $37.2 Million	132,795 Added 51.87%	388,805 $108 Million
Q3 2022 Nov 14, 2022	SELL	$203.3 - $244.17 $18.2 Million - $21.8 Million	-89,313 Reduced 25.86%	256,010 $53.6 Million
Q2 2022 Oct 27, 2022	SELL	$174.81 - $241.14 $6.47 Million - $8.93 Million	-37,034 Reduced 9.69%	345,323 $81.4 Million
Q2 2022 Aug 15, 2022	SELL	$174.81 - $241.14 $6.47 Million - $8.93 Million	-37,034 Reduced 9.69%	345,323 $81.4 Million
Q1 2022 Oct 27, 2022	BUY	$166.16 - $213.96 $6.15 Million - $7.92 Million	37,034 Added 10.72%	382,357 $68.6 Million
Q1 2022 May 13, 2022	BUY	$166.16 - $213.96 $38.7 Million - $49.8 Million	232,759 Added 155.59%	382,357 $68.6 Million
Q4 2021 Feb 14, 2022	BUY	$184.32 - $216.08 $7.44 Million - $8.72 Million	40,350 Added 36.93%	149,598 $32.3 Million
Q3 2021 Nov 15, 2021	BUY	$179.86 - $214.88 $19.6 Million - $23.5 Million	109,248 New	109,248 $20.2 Million

Others Institutions Holding UTHR

# of Institutions

668

Shares Held

42.8M

Call Options Held

194K

Put Options Held

295K

View Full List

About UNITED THERAPEUTICS Corp

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.6B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

More about UTHR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account